Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma.

Tsuchiya N, Narita S, Inoue T, Hasunuma N, Numakura K, Horikawa Y, Satoh S, Notoya T, Fujishima N, Hatakeyama S, Ohyama C, Habuchi T.

Anticancer Drugs. 2013 Mar;24(3):310-4. doi: 10.1097/CAD.0b013e32835c401c.

PMID:
23237922
2.

Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.

Fukudo M, Ito T, Mizuno T, Shinsako K, Hatano E, Uemoto S, Kamba T, Yamasaki T, Ogawa O, Seno H, Chiba T, Matsubara K.

Clin Pharmacokinet. 2014 Feb;53(2):185-96. doi: 10.1007/s40262-013-0108-z.

PMID:
24135988
3.

Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.

Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, Lee DH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.

Chemotherapy. 2012;58(6):468-74. doi: 10.1159/000346484. Epub 2013 Mar 20.

4.

Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.

Jäger D, Ma JH, Mardiak J, Ye DW, Korbenfeld E, Zemanova M, Ahn H, Guo J, Leonhartsberger N, Stauch K, Böckenhoff A, Yu J, Escudier B.

Clin Genitourin Cancer. 2015 Apr;13(2):156-64.e1. doi: 10.1016/j.clgc.2014.07.007. Epub 2014 Aug 23.

5.

Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.

Zhao J, Zhu Y, Zhang C, Wang X, He H, Wang H, Wu Y, Zhou W, Shen Z.

Urol Oncol. 2013 Nov;31(8):1800-5. doi: 10.1016/j.urolonc.2012.04.019. Epub 2012 May 31.

PMID:
22658883
6.

Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.

Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, Kobayashi M, Morita T.

Jpn J Clin Oncol. 2013 Oct;43(10):1023-9. doi: 10.1093/jjco/hyt110. Epub 2013 Aug 15.

PMID:
23956442
7.

The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.

Zheng Y, Wang F, Wu G, Zhang L, Wang Y, Wang Z, Chen P, Wang Q, Lu J, Wang Y, Li P, Wang J, Lu X, Yuan J.

Medicine (Baltimore). 2015 Dec;94(49):e2222. doi: 10.1097/MD.0000000000002222.

8.

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.

Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, Rosbrook B, Chen C, Kim S, Vogelzang NJ.

Lancet Oncol. 2013 Dec;14(13):1287-94. doi: 10.1016/S1470-2045(13)70465-0. Epub 2013 Oct 25.

PMID:
24206640
9.

Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.

Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, Vyzula R, Abrahamova J, Buchler T; Czech Renal Cancer Cooperative Group.

Ann Oncol. 2012 Dec;23(12):3137-43. doi: 10.1093/annonc/mds145. Epub 2012 Jun 13.

PMID:
22700990
10.

Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.

Li Y, Li S, Zhu Y, Liang X, Meng H, Chen J, Zhang D, Guo H, Shi B.

J Clin Hypertens (Greenwich). 2014 Mar;16(3):177-85. Review.

11.

Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.

Omae K, Kondo T, Kennoki T, Takagi T, Iizuka J, Kobayashi H, Hashimoto Y, Tanabe K.

Int J Clin Oncol. 2016 Feb;21(1):126-32. doi: 10.1007/s10147-015-0871-y. Epub 2015 Jul 11.

PMID:
26163345
12.

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.

Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, Durand JP, Coriat R, Dauphin A, Vidal M, Tod M, Loriot MA, Goldwasser F, Blanchet B.

PLoS One. 2012;7(8):e42875. doi: 10.1371/journal.pone.0042875. Epub 2012 Aug 13.

13.

[Side effects of sorafenib and countermeasures].

Nakayama M, Arai Y, Nishimura K.

Hinyokika Kiyo. 2012 Nov;58(11):635-7. Japanese.

14.

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis.

Procopio G, Bellmunt J, Dutcher J, Bracarda S, Knox J, Brueckner A, Molnar I, Escudier B, Hutson TE.

Br J Cancer. 2013 Feb 5;108(2):311-8. doi: 10.1038/bjc.2012.543. Epub 2013 Jan 15.

15.

Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.

Procopio G, Derosa L, Gernone A, Morelli F, Sava T, Zustovich F, De Giorgi U, Ferrari V, Sabbatini R, Gasparro D, Felici A, Burattini L, Calvani N, Lo Re G, Banna G, Pia Brizzi M, Rizzo M, Ciuffreda L, Iacovelli R, Ferraù F, Taibi E, Bracarda S, Porta C, Galligioni E, Contu A.

Future Oncol. 2014 Aug;10(10):1741-50. doi: 10.2217/fon.14.48. Epub 2014 Mar 18.

16.

A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.

Shinohara N, Nonomura N, Eto M, Kimura G, Minami H, Tokunaga S, Naito S.

Ann Oncol. 2014 Feb;25(2):472-6. doi: 10.1093/annonc/mdt541. Epub 2013 Dec 18.

PMID:
24351402
17.

A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma.

Wang HK, Zhang HL, Zhu Y, Yao XD, Zhang SL, Dai B, Shen YJ, Zhu YP, Shi GH, Qin XJ, Ma CG, Lin GW, Xiao WJ, Ye DW.

Future Oncol. 2014 Oct;10(12):1941-51. doi: 10.2217/fon.14.131.

PMID:
25386811
18.

A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.

Akaza H, Oya M, Iijima M, Hyodo I, Gemma A, Itoh H, Adachi M, Okayama Y, Sunaya T, Inuyama L.

Jpn J Clin Oncol. 2015 Oct;45(10):953-62. doi: 10.1093/jjco/hyv099. Epub 2015 Jul 22.

19.

Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.

Konca Degertekin C, Coşkun U, Baloş Törüner F, Aktürk M, Demirci U.

Endocrine. 2012 Dec;42(3):756-7. doi: 10.1007/s12020-012-9683-2. No abstract available.

PMID:
22562706
20.

Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.

Naito S, Sakai H, Hashine K, Tomita Y, Shinohara N, Fujisawa M, Eto M, Ozono S, Akaza H.

Ann Oncol. 2015 Sep;26(9):1871-6. doi: 10.1093/annonc/mdv280. Epub 2015 Jun 27.

PMID:
26117830

Supplemental Content

Support Center